{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:19:40Z","timestamp":1790507980642,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":442,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004046","name":"Karen Elise Jensens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004046","name":"Karen Elise Jensens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Wild-type transthyretin cardiac amyloidosis (ATTRwt) is a cardiomyopathy causing myocardial hypoperfusion and impaired cardiac mitochondrial function. Trimetazidine is an antianginal agent used in patients with stable angina pectoris, which improves cardiac contractility and mitochondrial function. The aim of the study was to investigate the effect of trimetazidine on invasive haemodynamics and cardiac mitochondrial function in ATTRwt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a randomized, double-blind, placebo-controlled, crossover trial, 22 patients with ATTRwt received 4 weeks of trimetazidine and placebo in randomized order. After each treatment period followed examinations with endomyocardial biopsies taken for high-resolution respirometry and right heart catheterization at rest and during a cardiopulmonary exercise test. The primary endpoint was mean pulmonary artery wedge pressure (mPAWP) during peak exercise. The secondary endpoint was cardiac mitochondrial oxidative phosphorylation capacity. Exploratory endpoints were echocardiographic parameters, cardiac biomarker levels and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Trimetazidine did not significantly reduce mPAWP during peak exercise (31 \u00b1 12 vs. 31 \u00b1 13 mmHg, P = 0.61) or improve the cardiac mitochondrial oxidative phosphorylation capacity (73.4 \u00b1 7.7 vs. 75.3 \u00b1 7.7 pmol O2\/(mg*s), P = 0.81) compared with placebo, nor did treatment with trimetazidine improve ejection fraction (P = 0.93), global longitudinal strain (P = 0.23), N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (P = 0.92) or the patients' quality of life (P = 0.98).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In ATTRwt, treatment with trimetazidine did not improve mPAWP or cardiac mitochondrial oxidative phosphorylation capacity compared with placebo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15181","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:40:02Z","timestamp":1733197202000},"page":"1796-1806","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of Trimetazidine On Cardiac Haemodynamics and Mitochondrial Function in Wild-Type Transthyretin Amyloidosis"],"prefix":"10.1093","volume":"12","author":[{"given":"Bertil Thyrsted","family":"Ladefoged","sequence":"first","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Lehmann Dahl","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Mette","family":"Dybro","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Skibsted","family":"Clemmensen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, Royal Free Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"2026021804233199900_ehf215181-bib-0001","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2026021804233199900_ehf215181-bib-0002","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2026021804233199900_ehf215181-bib-0003","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jcmg.2023.01.024","article-title":"Association of right ventricular myocardial blood flow with pulmonary pressures and outcome in cardiac amyloidosis","volume":"16","author":"Harms","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026021804233199900_ehf215181-bib-0004","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026021804233199900_ehf215181-bib-0005","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13506129.2003.12088562","article-title":"Cellular consequences of transthyretin deposition","volume":"10","author":"Saraiva","year":"2003","journal-title":"Amyloid"},{"key":"2026021804233199900_ehf215181-bib-0006","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1021\/acs.biochem.2c00390","article-title":"Toxic misfolded transthyretin oligomers with different molecular conformations formed through distinct oligomerization pathways","volume":"61","author":"Dasari","year":"2022","journal-title":"Biochemistry"},{"key":"2026021804233199900_ehf215181-bib-0007","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021804233199900_ehf215181-bib-0008","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021804233199900_ehf215181-bib-0009","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021804233199900_ehf215181-bib-0010","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/hrt.2010.208751","article-title":"Trimetazidine: a meta-analysis of randomised controlled trials in heart failure","volume":"97","author":"Gao","year":"2011","journal-title":"Heart"},{"key":"2026021804233199900_ehf215181-bib-0011","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2011.11.027","article-title":"Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis","volume":"59","author":"Zhang","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026021804233199900_ehf215181-bib-0012","doi-asserted-by":"publisher","first-page":"112","DOI":"10.15420\/cfr.2015.1.2.112","article-title":"Metabolic therapy in heart failure","volume":"1","author":"Lopatin","year":"2015","journal-title":"Card Fail Rev"},{"key":"2026021804233199900_ehf215181-bib-0013","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"2026021804233199900_ehf215181-bib-0014","doi-asserted-by":"publisher","first-page":"175","DOI":"10.14744\/AnatolJCardiol.2017.7771","article-title":"Effects of trimetazidine on mitochondrial respiratory function, biosynthesis, and fission\/fusion in rats with acute myocardial ischemia","volume":"18","author":"Shi","year":"2017","journal-title":"Anatol J Cardiol"},{"key":"2026021804233199900_ehf215181-bib-0015","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/cvr\/cvq181","article-title":"Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase\u2013ROS\u2013CTGF pathway","volume":"88","author":"Liu","year":"2010","journal-title":"Cardiovasc Res"},{"key":"2026021804233199900_ehf215181-bib-0016","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.707399","article-title":"Trimetazidine attenuates heart failure by improving myocardial metabolism via AMPK","volume":"12","author":"Shu","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026021804233199900_ehf215181-bib-0017","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021804233199900_ehf215181-bib-0018","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804233199900_ehf215181-bib-0019","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026021804233199900_ehf215181-bib-0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"2026021804233199900_ehf215181-bib-0021","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.amjcard.2014.04.011","article-title":"Effects of healthy aging on the cardiopulmonary hemodynamic response to exercise","volume":"114","author":"van Empel","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026021804233199900_ehf215181-bib-0022","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jchf.2016.10.012","article-title":"The influence of age on hemodynamic parameters during rest and exercise in healthy individuals","volume":"5","author":"Wolsk","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026021804233199900_ehf215181-bib-0023","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med"},{"key":"2026021804233199900_ehf215181-bib-0024","doi-asserted-by":"publisher","DOI":"10.26124\/bec:2020-0002","article-title":"Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 5th ed","volume":"2020","author":"Gnaiger","year":"2020","journal-title":"Bioenerg Commun"},{"key":"2026021804233199900_ehf215181-bib-0025","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/ejhf.899","article-title":"Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis","volume":"19","author":"Clemmensen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026021804233199900_ehf215181-bib-0026","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1183\/09031936.00194909","article-title":"The 6-min walk distance in healthy subjects: reference standards from seven countries","volume":"37","author":"Casanova","year":"2011","journal-title":"Eur Respir J"},{"key":"2026021804233199900_ehf215181-bib-0027","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.hfc.2014.03.001","article-title":"Invasive hemodynamic characterization of heart failure with preserved ejection fraction","volume":"10","author":"Andersen","year":"2014","journal-title":"Heart Fail Clin"},{"key":"2026021804233199900_ehf215181-bib-0028","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1002\/ehf2.14418","article-title":"Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial","volume":"10","author":"van de Bovenkamp","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026021804233199900_ehf215181-bib-0029","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.healun.2022.01.1376","article-title":"Abnormal mitochondrial function and morphology in heart transplanted patients with cardiac allograft vasculopathy","volume":"41","author":"Lichscheidt","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2026021804233199900_ehf215181-bib-0030","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.biochi.2012.07.011","article-title":"What does make an amyloid toxic: morphology, structure or interaction with membrane?","volume":"95","author":"Berthelot","year":"2013","journal-title":"Biochimie"},{"key":"2026021804233199900_ehf215181-bib-0031","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.fjc.0000164091.81198.a3","article-title":"The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury","volume":"46","author":"Tritto","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026021804233199900_ehf215181-bib-0032","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5582\/ddt.2022.01020","article-title":"Trimetazidine improves left ventricular global longitudinal strain value in patients with heart failure with reduced ejection fraction due to ischemic heart disease","volume":"16","author":"Harjoko","year":"2022","journal-title":"Drug Discov Ther"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1796\/66955872\/eschf_12_3_1796.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1796\/66955872\/eschf_12_3_1796.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:23:37Z","timestamp":1771406617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/1796\/8488300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,3]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15181","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"2024-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}